(CercleFinance.com) – Néovacs announces a fundraising of 1 ME by drawing 1 tranche of OCEANE-BSA, with a nominal value of 1,000,000 E, subscribed by European High Growth Opportunities Securitization Fund.
The net proceeds from this operation (E960,000) will be 50% intended to finance the Kinoïde® research program on allergies and 50% to strengthen investment capacities in promising projects, both in the development of drug candidates (BioTech) and medical devices (MedTech).
The drawing of 1 tranche of OCEANE-BSA announced today gives rise to the issue of 114,942,528 BSA which will be retroceded to Néovacs with a view to their cancellation and could give rise to the creation of 283,687,943 new shares on the basis of the last quoted price.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
